{"groups":[{"description":"Participants were administered LBH589 (panobinostat)in combination with bortezomib and dexamethasone 2 weeks on/1 week off.","id":"FG000","title":"LBH589 + Bortezomib + Dexamethasone"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"20"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Progressive disease"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Study terminated by Sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Physician Decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"31"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"27"}],"type":"Subjects. Discont. Prematurely"},{"achievements":[{"groupId":"FG000","numSubjects":"8"}],"type":"Subjects Completed Study Per Protocol"},{"achievements":[{"groupId":"FG000","numSubjects":"31"}],"type":"Subjs. Ntered Post-treatment Eval. Phase"},{"achievements":[{"groupId":"FG000","numSubjects":"24"}],"type":"Subjects Entered Survival f/u Phase"},{"achievements":[{"groupId":"FG000","numSubjects":"17"}],"type":"Entered Treatment Phase 2"},{"achievements":[{"groupId":"FG000","numSubjects":"4"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"27"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Approximately 33 eligible subjects were planned to be enrolled. 31 eligible subjects were enrolled and treated with PAN+BTZ+Dex (Treatment phase 1), of which 17 subjects entered Treatment phase 2. All 31 subjects entered the post-treatment evaluation phase, of which 22 discontinued the study. 24 subjects entered the survival follow-up phase."}